Biocon: Benefitted by biopharma
(Jan 21, 2010)
Revenues for 3QFY10 grow by a robust 46% YoY, led by the strong performance of both its biopharmaceuticals and contract research businesses. EBDITA margins fall by 3.8% during the quarter on the back of a rise in raw material costs and other expenses (as percentage of sales). While the bottomline grows at a stupendous pace during the quarter, the same is largely due to the forex loss incurred in 3QFY09, which is not present this quarter. On excluding the same, growth in bottomline stands at 15% YoY.

Biocon: Biopharma's stellar show
(Oct 22, 2009)
Revenues for 2QFY10 grow by a robust 30% YoY, led by the strong performance of the both its biopharmaceuticals and contract research businesses. EBDITA margins improve by 2% during the quarter on the back of a fall in other expenditure (as percentage of sales). Bottomline during the quarter grows by 47% YoY growth on excluding the forex loss that was reported in 2QFY09, which was not present this quarter.

Biocon: The power of niche
(Jul 23, 2009)
Revenues for 1QFY10 grow by a robust 88% YoY, led by the strong performance of the biopharmaceuticals (including the acquired company AxiCorp) and contract research businesses. EBDITA margins contract by 4.4% during the quarter on the back of a considerable rise in raw material costs (as percentage of sales). Bottomline during the quarter registers a 23% YoY growth on excluding the forex loss that was reported in 1QFY09, which was not present this quarter.

Biocon: Bearing the 'AxiCorp' burden
(May 4, 2009)
Revenues for FY09 grow by a robust 53% YoY, led by the strong performance of the biopharmaceuticals (including the acquired company AxiCorp) and contract research businesses. EBDITA margins contract by 8.1% during the year on the back of a considerable rise in raw material and staff costs (both as percentage of sales). Bottomline during the year tumbles by 80% YoY. However, if we exclude the extraordinary items during both FY08 and FY09, then the bottomline registers a 7% YoY growth.

Biocon: Marred by forex losses
(Jan 21, 2009)
Revenues for 3QFY09 grow by a robust 84% YoY, led by the strong performance of the biopharmaceuticals (including the acquired company AxiCorp) and contract research businesses. EBDITA margins contract by 1.4% during the quarter on the back of a considerable rise in raw material and staff costs (both as percentage of sales). Bottomline during the quarter tumbles by 90% YoY. However, if we exclude the extraordinary items during both 3QFY08 and 3QFY09, then the bottomline registers a 39% YoY growth.

Biocon: Profits at the receiving end
(Oct 16, 2008)
Revenues for 2QFY09 grow by a robust 59% YoY, led by the strong performance of the biopharmaceuticals (including the acquired company AxiCorp) and contract research businesses. EBDITA margins contract substantially by 9% during the quarter on the back of a considerable rise in raw material costs and other expenditure (both as percentage of sales). The company reports a loss at the net level of Rs 5 m. However, if we exclude the extraordinary expense (market to market losses), then the bottomline registers an 11% YoY growth backed by higher other income.

Biocon: All fall down
(Jul 17, 2008)
Revenues for 1QFY09 fall by 3% YoY largely due to a poor show put up by the contract research business and absence of license fees and revenues from enzymes during the quarter. EBDITA margins contract by a substantial 470 basis points (4.7%) during the quarter on the back of a considerable rise in raw material costs and R&D expenditure (both as percentage of sales). PAT tumbles by 72% YoY owing to the fall in operating profits, higher depreciation and mark to market losses incurred. If we exclude the latter, then the fall in bottomline is relatively less steeper at 24% YoY.

Biocon: Biopharma benefits
(Apr 22, 2008)
Revenues for FY08 grow by 7% YoY largely driven by the strong performances of both the biopharmaceuticals and contract research businesses. EBDITA margins contract by 30 basis points (0.3%) during the year on the back of a considerable rise in staff costs and other expenses (both as percentage of sales). PAT grows by 13% YoY (excluding the extraordinary income) and is aided by a lower tax outgo and rise in other income despite higher depreciation charges. Acquires 70% stake in a German pharma company AxiCorp to strengthen its focus on biosimilars. Recommends a special dividend of Rs 2 per share (dividend yield of 0.4%) pursuant to the divestment of the enzymes business. Board recommends a bonus issue in the ratio 1:1.

Biocon: Biopharma drives growth
(Jan 17, 2008)
Revenues for 9mFY08 grow by 11% YoY largely driven by the strong performances of both the biopharmaceuticals and contract research businesses. However, sharp rupee appreciation hampers revenue growth in the contract research business. EBDITA margins contract by 30 basis points (0.3%) during the nine-month period on the back of a considerable rise in staff costs and other expenses (both as percentage of sales). PAT growth at 15% YoY is aided by a lower tax outgo despite higher interest costs and depreciation charges. Announces a strategic partnership with IATRICa Inc, a US based biotech company to co-develop molecules catering to the therapeutic areas of cancer and infectious diseases. Plans to list its 100% subsidiary Syngene on the Indian bourses during FY09.

Biocon: Contract research rules
(Oct 18, 2007)
Revenues for 1HFY08 grow by 19% YoY largely driven by the strong performances of both the biopharmaceuticals and contract research businesses. EBDITA margins expand by 250 basis points (2.5%) on the back of a considerable fall in raw material costs (as percentage of sales). PAT growth at 27% YoY - aided by the strong performance at the operating level and a lower tax outgo. Completes divestment of enzymes business (around 8% of revenues) to Novozymes South Asia Pvt Ltd, a wholly owned subsidiary of Novozymes A/S of Denmark for a gross consideration of Rs 4.6 bn.